The Measles virus is a highly contagious single-stranded RNA virus that is mostly spread via the respiratory system. It may be passed via aerosol droplets from coughs or through contact with infected bodily fluids. It causes measles, a disease characterised by fever, cough, runny nose, red eyes and a rash. Most patients with uncomplicated measles will recover without antiviral treatment, however, some patients may develop diarrhoea, corneal ulceration, pneumonia or encephalitis. Complications are more likely in adults. In developed countries, most children are immunised against measles by the age of 18 months, as part of the three-part MMR (measles, mumps and rubella) vaccine.
- Target Species
- Product Form
- Inactivated Measles virus - liquid
- Measles virus, Edmonston strain, cultured in Vero cells. Optimally infected cells are disrupted in culture fluids. The suspension is clarified and concentrated by crossflow ultrafiltration. The antigen preparation is inactivated using gamma radiation, which primarily damages viral genetic material.
- Buffer Solution
- Minimum Essential Medium
- Preservative Stabilisers
- None present
- This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately.
- Approx. Protein Concentrations
- Please see label for concentration
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.
- 18 months from date of despatch
- For research purposes only
Applications of Measles Virus
|Application Name||Verified||Min Dilution||Max Dilution|
- Instructions For Use
- PIP013 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats or may be further purified to meet the requirements of a particular assay format.
Product Specific References
References for Measles Virus
Bhoj, V.G. et al. (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.
Blood. 128 (3): 360-70.